Long-term, Open Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of QCC374 in Patients With Pulmonary Arterial Hypertension (PAH)
Latest Information Update: 30 Jul 2020
Price :
$35 *
At a glance
- Drugs QCC 374 (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 17 Feb 2020 Status changed to discontinued.
- 24 Nov 2018 This trial has been Discontinued in Germany , according to European Clinical Trials Database.
- 26 Sep 2018 This trial was completed in Germany, according to European Clinical Trials Database.